Healthcare Industry News: Mylan
News Release - March 23, 2007
Pfizer Announces Launch of Generic Amlodipine Besylate Product by GreenstoneNEW YORK--(HSMN NewsFeed)--In response to an announcement today by Mylan Laboratories that it has launched a generic competitor to Norvasc, Pfizer said it is making available its own generic amlodipine besylate product immediately through the company's Greenstone subsidiary. Norvasc also will remain available to patients.
Pfizer said it will continue to pursue all available legal remedies to protect the market for Norvasc through a six-month pediatric exclusivity period that expires in September, 2007.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.
Related News ItemsAmplyx Pharmaceuticals Adds Pfizer and Adage to Series C Financing, Bringing Total to over 90 Million
EMD Serono and Pfizer Receive US FDA Breakthrough Therapy Designation and Submit Application for BAVENCIO(R) for First-Line Maintenance Treatment of Locally Advanced or Metastatic Urothelial Carcinoma
EMD Serono and Pfizer Provide Update on Phase III JAVELIN Head and Neck 100 Study